Stanley Laman Group Ltd. acquired a new stake in Selecta Biosciences Inc (NASDAQ:SELB) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 40,964 shares of the company’s stock, valued at approximately $402,000. Stanley Laman Group Ltd. owned approximately 0.18% of Selecta Biosciences at the end of the most recent quarter.
Other institutional investors have also added to or reduced their stakes in the company. Virtu Financial LLC bought a new position in Selecta Biosciences during the fourth quarter worth about $306,000. BlackRock Inc. boosted its position in shares of Selecta Biosciences by 7.1% in the fourth quarter. BlackRock Inc. now owns 620,229 shares of the company’s stock valued at $6,085,000 after acquiring an additional 41,264 shares during the period. Wells Fargo & Company MN boosted its position in shares of Selecta Biosciences by 125.8% in the fourth quarter. Wells Fargo & Company MN now owns 23,491 shares of the company’s stock valued at $230,000 after acquiring an additional 13,086 shares during the period. Keybank National Association OH bought a new stake in Selecta Biosciences during the fourth quarter valued at approximately $143,000. Finally, Polaris Venture Management Co. V L.L.C. lifted its position in Selecta Biosciences by 18.2% during the fourth quarter. Polaris Venture Management Co. V L.L.C. now owns 1,924,151 shares of the company’s stock valued at $18,876,000 after purchasing an additional 296,624 shares during the last quarter. 50.20% of the stock is currently owned by hedge funds and other institutional investors.
Several research analysts have commented on SELB shares. Canaccord Genuity reissued a “buy” rating on shares of Selecta Biosciences in a research note on Wednesday, January 3rd. ValuEngine downgraded shares of Selecta Biosciences from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Mizuho began coverage on shares of Selecta Biosciences in a research report on Monday, February 26th. They set a “buy” rating and a $30.00 price objective on the stock. Finally, Zacks Investment Research cut shares of Selecta Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. Selecta Biosciences currently has a consensus rating of “Hold” and a consensus target price of $24.80.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.